Eli Lilly and Company
Lysophosphatidic acid receptor 1 (LPAR1) inhibitor compounds
Last updated:
Abstract:
The present invention provides a compound of formula (I) or a pharmaceutical salt thereof, use, methods for its preparation are described. ##STR00001##
Status:
Grant
Type:
Utility
Filling date:
28 Aug 2018
Issue date:
21 Jun 2022